Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "EULAR"

15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions

Michele B. Kaufman, PharmD, BCGP  |  October 17, 2024

Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.

Lupus: Closer to a Cause?

Samantha C. Shapiro, MD  |  September 20, 2024

Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.

The Rheumatologist’s Role in Sarcoidosis

Samantha C. Shapiro, MD  |  August 26, 2024

Rheumatologists are uniquely positioned to care for patients with sarcoidosis. Here are insights into the condition, its treatment and more.

A World View: The ACR Global Research Exchange Program Promotes Mentorship & Long-Term Collaboration in Rheumatology

Ruth Jessen Hickman, MD  |  February 15, 2024

2023 marks the post-pandemic return of research exchanges hosted by the ACR & EULAR to benefit junior academic rheumatologists & rheumatology professionals.

The Importance of Health Literacy in Clinical Care

Jason Liebowitz, MD, FACR  |  August 14, 2023

EULAR 2023—It is not enough to practice medicine by the book; rather, communication with patients and understanding their goals for patients are vital to high-quality care. At EULAR 2023, the session titled The Promise of Health Literacy in Clinical Care provided a treasure trove of insights for many clinicians. Definitions & Actions The first speaker…

Point-of-Care Uric Acid Testing

Samantha C. Shapiro, MD  |  March 1, 2023

In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for…

Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw

Michele B. Kaufman, PharmD, BCGP  |  December 12, 2022

A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.

Difficult-to-Treat RA Definition & Management Considerations

Samantha C. Shapiro, MD  |  November 10, 2022

Despite an expanding arma­mentarium of disease-modifying treatments for rheumatoid arthritis (RA), some patients with RA remain sympto­matic.1 Current treatment guidelines from both the ACR and the European Alliance of Associations for Rheumatology (EULAR) recommend treat-to-target strategies to achieve remission or low disease activity, and patients want to feel better.2,3 So how can we best help…

TNF Inhibitors Associated with Neurological Adverse Events

Michele B. Kaufman, PharmD, BCGP  |  November 7, 2022

A study examined the association between TNF inhibitors and neurological demyelinating adverse events in patients with rheumatoid arthritis and spondyloarthritis using cohort data from five Nordic countries. Researchers showed that patients with SpA were more likely to experience adverse events than patients with RA.

What’s New in SLE: Pathogenesis & Novel Therapies

Samantha C. Shapiro, MD  |  September 8, 2022

Thomas Dörner, MD, reviewed the current state of systemic lupus erythematosus (SLE) management, providing updates on novel therapies and insights into the pathogenesis of SLE.

  • 1
  • 2
  • 3
  • …
  • 16
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences